Evofem Biosciences, Inc. has announced a 1-for-1,500 reverse stock split of its common stock, which took effect at the open of trading on the OTCID marketplace on November 18, 2026. The reverse split was approved by stockholders at the company’s Annual Meeting of Stockholders held on November 26, 2025. The common stock will initially trade on the OTCID under the symbol EVFMD, and after twenty (20) business days, it will continue trading on the OTCID under the symbol EVFM. The new CUSIP number assigned to the common stock following the reverse split is 30048L401.
Evofem Biosciences stated that the reverse stock split is intended to ensure the company maintains a sufficient number of authorized shares of common stock to cover the shares underlying its financial instruments on a fully diluted basis. Under the 1-for-1,500 ratio, every 1,500 existing shares of common stock will be automatically converted into one share. The consolidation will reduce the number of outstanding common shares from approximately 132,530,081 — the total outstanding as of November 17, 2026, which served as the Record Date for the transaction — to approximately 88,353 shares.
Any stockholder who would otherwise be entitled to a fractional share of common stock resulting from the reverse split will instead receive a cash payment equal to the product of the resulting fractional interest in one share multiplied by the closing trading price of the common stock on the trading day immediately preceding the effective time, which was $0.0043.

